70 related articles for article (PubMed ID: 35979118)
1. Dacomitinib exhibits promising activity against the rare
Yang G; Liu R; Tang X
Heliyon; 2024 May; 10(9):e30312. PubMed ID: 38707278
[TBL] [Abstract][Full Text] [Related]
2. Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib.
Liu J; Lin S; Huynh A; Tan W
Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38258127
[TBL] [Abstract][Full Text] [Related]
3. Treating epidermal growth factor receptor-mutated non-small cell lung cancer-is dacomitinib the winner?
Dempke WCM; Fenchel K
Transl Lung Cancer Res; 2017 Dec; 6(Suppl 1):S88-S91. PubMed ID: 29300395
[No Abstract] [Full Text] [Related]
4. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
6. Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report.
Xu F; Xia ML; Pan HY; Pan JW; Shen YH
World J Clin Cases; 2022 Jun; 10(17):5916-5922. PubMed ID: 35979118
[TBL] [Abstract][Full Text] [Related]
7. Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report.
An N; Wang H; Zhu H; Yan W; Jing W; Kong L; Zhang Y; Yu J
Onco Targets Ther; 2019; 12():7399-7404. PubMed ID: 31686847
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
[TBL] [Abstract][Full Text] [Related]
9. EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report.
Valcárcel S; Villanueva N; Álvarez C; Esteban E
Anticancer Drugs; 2024 Mar; ():. PubMed ID: 38513159
[TBL] [Abstract][Full Text] [Related]
10. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
Ibrahim U; Saqib A; Atallah JP
Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
[TBL] [Abstract][Full Text] [Related]
11. Clinical Utility of Targeted Sequencing in Lung Cancer: Experience From an Autonomous Swedish Health Care Center.
Isaksson S; Hazem B; Jönsson M; Reuterswärd C; Karlsson A; Griph H; Engleson J; Oskarsdottir G; Öhman R; Holm K; Rosengren F; Annersten K; Jönsson G; Borg Å; Edsjö A; Levéen P; Brunnström H; Lindquist KE; Staaf J; Planck M
JTO Clin Res Rep; 2020 Mar; 1(1):100013. PubMed ID: 34589915
[TBL] [Abstract][Full Text] [Related]
12. Complete Response to Afatinib of an EGFR Exon 18 delE709_T710insD-Mutated Stage IV Lung Adenocarcinoma.
Jelli B; Taton O; D'Haene N; Remmelink M; Mekinda Z
Eur J Case Rep Intern Med; 2021; 8(8):002749. PubMed ID: 34527619
[TBL] [Abstract][Full Text] [Related]
13. A Lung Adenocarcinoma Patient With a Rare
Wei Y; Cui Y; Guo Y; Li L; Zeng L
Front Oncol; 2021; 11():700345. PubMed ID: 34178699
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
